{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:20:18Z","timestamp":1760782818265},"reference-count":47,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To determine whether low-dose tamoxifen and fenretinide have a synergistic effect on surrogate biomarkers, including circulating insulin-like growth factor I (IGF-I) and mammographic density, in premenopausal women at risk for breast cancer and to study drug safety. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Premenopausal women (n = 235) were randomly assigned in a double-blind four-arm trial to receive tamoxifen 5 mg\/d, fenretinide 200 mg\/d, both agents, or placebo for 2 years. The present analysis refers to preliminary data on safety, IGF-I, and breast cancer events. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Patients were included if they had an excised ductal carcinoma-in-situ (57%), lobular carcinoma-in-situ (13%), minimal invasive breast cancer (7%), or a 5-year Gail risk \u2265 1.3% (23%). After a median follow-up of 40 months, there was a reduction of 13%, 2%, 20%, and 1% in IGF-I levels for patients on tamoxifen, fenretinide, tamoxifen plus fenretinide, and placebo, respectively. Recruitment was stopped based on the lack of an interaction on IGF-I levels, which was a primary end point for the study. Thirty-six patients have dropped out of the study, 17 because of adverse events and 19 for various other reasons. One stage I endometrial cancer occurred in a patient on fenretinide, and one optic nerve ischemia and one deep venous thrombosis occurred on tamoxifen. There was no difference in menopausal symptoms, endometrial thickness, polyps, or ovarian cysts among treatment arms. To date, 24 breast cancers have been observed, without differences among arms. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> The combination of low-dose tamoxifen and fenretinide is safe but not synergistic in lowering IGF-I levels in premenopausal women. The clinical implications require further follow-up. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.02.9934","type":"journal-article","created":{"date-parts":[[2005,12,28]],"date-time":"2005-12-28T23:33:25Z","timestamp":1135812805000},"page":"129-135","source":"Crossref","is-referenced-by-count":37,"title":["Preliminary Results on Safety and Activity of a Randomized, Double-Blind, 2 \u00d7 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in Premenopausal Women"],"prefix":"10.1200","volume":"24","author":[{"given":"Aliana","family":"Guerrieri-Gonzaga","sequence":"first","affiliation":[{"name":"From the Divisions of Chemoprevention, Breast Surgery, Breast Diagnostics, Gynaecologic Surgery, and Pathology, European Institute of Oncology; Chemoprevention Unit, National Cancer Institute, Milan; Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, Genoa; Division of Medical Oncology, Ospedale S. Bortolo, Vicenza, Italy; Department of Statistics and Modelling Science, Strathclyde University, Glasgow, Scotland, United Kingdom; and Division of Cancer Prevention, National Cancer..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Robertson","sequence":"additional","affiliation":[{"name":"From the Divisions of Chemoprevention, Breast Surgery, Breast Diagnostics, Gynaecologic Surgery, and Pathology, European Institute of Oncology; Chemoprevention Unit, National Cancer Institute, Milan; Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, Genoa; Division of Medical Oncology, Ospedale S. Bortolo, Vicenza, Italy; Department of Statistics and Modelling Science, Strathclyde University, Glasgow, Scotland, United Kingdom; and Division of Cancer Prevention, National Cancer..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Bonanni","sequence":"additional","affiliation":[{"name":"From the Divisions of Chemoprevention, Breast Surgery, Breast Diagnostics, Gynaecologic Surgery, and Pathology, European Institute of Oncology; Chemoprevention Unit, National Cancer Institute, Milan; Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, Genoa; Division of Medical Oncology, Ospedale S. Bortolo, Vicenza, Italy; Department of Statistics and Modelling Science, Strathclyde University, Glasgow, Scotland, United Kingdom; and Division of Cancer Prevention, National Cancer..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Serrano","sequence":"additional","affiliation":[{"name":"From the Divisions of Chemoprevention, Breast Surgery, Breast Diagnostics, Gynaecologic Surgery, and Pathology, European Institute of Oncology; Chemoprevention Unit, National Cancer Institute, Milan; Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, Genoa; Division of Medical Oncology, Ospedale S. Bortolo, Vicenza, Italy; Department of Statistics and Modelling Science, Strathclyde University, Glasgow, Scotland, United Kingdom; and Division of Cancer Prevention, National Cancer..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Cazzaniga","sequence":"additional","affiliation":[{"name":"From the Divisions of Chemoprevention, Breast Surgery, Breast Diagnostics, Gynaecologic Surgery, and Pathology, European Institute of Oncology; Chemoprevention Unit, National Cancer Institute, Milan; Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, Genoa; Division of Medical Oncology, Ospedale S. Bortolo, Vicenza, Italy; Department of Statistics and Modelling Science, Strathclyde University, Glasgow, Scotland, United Kingdom; and Division of Cancer Prevention, National Cancer..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Mora","sequence":"additional","affiliation":[{"name":"From the Divisions of Chemoprevention, Breast Surgery, Breast Diagnostics, Gynaecologic Surgery, and Pathology, European Institute of Oncology; Chemoprevention Unit, National Cancer Institute, Milan; Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, Genoa; Division of Medical Oncology, Ospedale S. Bortolo, Vicenza, Italy; Department of Statistics and Modelling Science, Strathclyde University, Glasgow, Scotland, United Kingdom; and Division of Cancer Prevention, National Cancer..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcella","family":"Gulisano","sequence":"additional","affiliation":[{"name":"From the Divisions of Chemoprevention, Breast Surgery, Breast Diagnostics, Gynaecologic Surgery, and Pathology, European Institute of Oncology; Chemoprevention Unit, National Cancer Institute, Milan; Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, Genoa; Division of Medical Oncology, Ospedale S. Bortolo, Vicenza, Italy; Department of Statistics and Modelling Science, Strathclyde University, Glasgow, Scotland, United Kingdom; and Division of Cancer Prevention, National Cancer..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriet","family":"Johansson","sequence":"additional","affiliation":[{"name":"From the Divisions of Chemoprevention, Breast Surgery, Breast Diagnostics, Gynaecologic Surgery, and Pathology, European Institute of Oncology; Chemoprevention Unit, National Cancer Institute, Milan; Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, Genoa; Division of Medical Oncology, Ospedale S. Bortolo, Vicenza, Italy; Department of Statistics and Modelling Science, Strathclyde University, Glasgow, Scotland, United Kingdom; and Division of Cancer Prevention, National Cancer..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franca","family":"Formelli","sequence":"additional","affiliation":[{"name":"From the Divisions of Chemoprevention, Breast Surgery, Breast Diagnostics, Gynaecologic Surgery, and Pathology, European Institute of Oncology; Chemoprevention Unit, National Cancer Institute, Milan; Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, Genoa; Division of Medical Oncology, Ospedale S. Bortolo, Vicenza, Italy; Department of Statistics and Modelling Science, Strathclyde University, Glasgow, Scotland, United Kingdom; and Division of Cancer Prevention, National Cancer..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Intra","sequence":"additional","affiliation":[{"name":"From the Divisions of Chemoprevention, Breast Surgery, Breast Diagnostics, Gynaecologic Surgery, and Pathology, European Institute of Oncology; Chemoprevention Unit, National Cancer Institute, Milan; Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, Genoa; Division of Medical Oncology, Ospedale S. Bortolo, Vicenza, Italy; Department of Statistics and Modelling Science, Strathclyde University, Glasgow, Scotland, United Kingdom; and Division of Cancer Prevention, National Cancer..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antuono","family":"Latronico","sequence":"additional","affiliation":[{"name":"From the Divisions of Chemoprevention, Breast Surgery, Breast Diagnostics, Gynaecologic Surgery, and Pathology, European Institute of Oncology; Chemoprevention Unit, National Cancer Institute, Milan; Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, Genoa; Division of Medical Oncology, Ospedale S. Bortolo, Vicenza, Italy; Department of Statistics and Modelling Science, Strathclyde University, Glasgow, Scotland, United Kingdom; and Division of Cancer Prevention, National Cancer..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorella","family":"Franchi","sequence":"additional","affiliation":[{"name":"From the Divisions of Chemoprevention, Breast Surgery, Breast Diagnostics, Gynaecologic Surgery, and Pathology, European Institute of Oncology; Chemoprevention Unit, National Cancer Institute, Milan; Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, Genoa; Division of Medical Oncology, Ospedale S. Bortolo, Vicenza, Italy; Department of Statistics and Modelling Science, Strathclyde University, Glasgow, Scotland, United Kingdom; and Division of Cancer Prevention, National Cancer..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Pelosi","sequence":"additional","affiliation":[{"name":"From the Divisions of Chemoprevention, Breast Surgery, Breast Diagnostics, Gynaecologic Surgery, and Pathology, European Institute of Oncology; Chemoprevention Unit, National Cancer Institute, Milan; Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, Genoa; Division of Medical Oncology, Ospedale S. Bortolo, Vicenza, Italy; Department of Statistics and Modelling Science, Strathclyde University, Glasgow, Scotland, United Kingdom; and Division of Cancer Prevention, National Cancer..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Johnson","sequence":"additional","affiliation":[{"name":"From the Divisions of Chemoprevention, Breast Surgery, Breast Diagnostics, Gynaecologic Surgery, and Pathology, European Institute of Oncology; Chemoprevention Unit, National Cancer Institute, Milan; Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, Genoa; Division of Medical Oncology, Ospedale S. Bortolo, Vicenza, Italy; Department of Statistics and Modelling Science, Strathclyde University, Glasgow, Scotland, United Kingdom; and Division of Cancer Prevention, National Cancer..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Decensi","sequence":"additional","affiliation":[{"name":"From the Divisions of Chemoprevention, Breast Surgery, Breast Diagnostics, Gynaecologic Surgery, and Pathology, European Institute of Oncology; Chemoprevention Unit, National Cancer Institute, Milan; Division of Medical and Preventive Oncology, E.O. Ospedali Galliera, Genoa; Division of Medical Oncology, Ospedale S. Bortolo, Vicenza, Italy; Department of Statistics and Modelling Science, Strathclyde University, Glasgow, Scotland, United Kingdom; and Division of Cancer Prevention, National Cancer..."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.11.2758"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09962-2"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.9.645"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.11.779"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025779120649"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.21.1847"},{"key":"R9","unstructured":"Torrisi R, Pensa F, Orengo MA, et al: The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res 53:4769,1993-4771,"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980610)76:6<787::AID-IJC3>3.0.CO;2-U"},{"key":"R11","unstructured":"Decensi A, Veronesi U, Miceli R, et al: Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res 9:4722,2003-4729,"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)10384-1"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20001201)88:5<828::AID-IJC22>3.0.CO;2-8"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-04-0561"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.19.1461"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.9.670"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.21.1622"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh106"},{"key":"R19","unstructured":"O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al: Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development. Clin Cancer Res 8:314,2002-346,"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006216409688"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.275"},{"key":"R22","unstructured":"Singletary SE, Atkinson EN, Hoque A, et al: Phase II clinical trial of N-(4-Hydroxyphenyl) retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 8:2835,2002-2842,"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.10.2036"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5122(96)01038-9"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Goldstein SR, Scheele WH, Rajagopalan SK, et al: A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 95:95,2000-103,","DOI":"10.1016\/S0029-7844(99)00502-5"},{"key":"R26","unstructured":"McCormick DL, Mehta RG, Thompson CA, et al: Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy. Cancer Res 42:508,1982-512,"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/7.2.193"},{"key":"R28","unstructured":"Moon RC, Kelloff GJ, Detrisac CJ, et al: Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res 12:1147,1992-1153,"},{"key":"R29","unstructured":"Ratko TA, Detrisac CJ, Dinger NM, et al: Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 49:4472,1989-4476,"},{"key":"R30","unstructured":"Zujewski J, Lawrence J, Lemon S, et al: Pilot trial of tamoxifen (tam) and fenretinide (4-HPR) in women at high risk of developing invasive breast cancer. Proc Am Assoc Cancer Res 38:46,1997,  (abstr 1763)"},{"key":"R31","unstructured":"Cobleigh MA, Gray R, Graham M, et al: Fenretinide (FEN) vs placebo in postmenopausal breast cancer patients receiving adjuvant tamoxifen (TAM): An Eastern Cooperative Oncology Group phase III intergroup trial (EB193, INT-0151). Proc Am Soc Clin Oncol 19:86a,2000,  (abstr 328)"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.12.083"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Veronesi U, Maisonneuve P, Costa A, et al: Drop-outs in tamoxifen prevention trials. Lancet 353:244,1999,","DOI":"10.1016\/S0140-6736(05)77261-5"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2659"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)85012-5"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.20.3464"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006142904301"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.434"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690280"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.20.1488"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00441-4"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010901)92:5<1151::AID-CNCR1433>3.0.CO;2-Y"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1269"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2003.09.048"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.2001.81.3.1269"},{"key":"R46","unstructured":"Decensi A, Johansson H, Miceli R, et al: Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer. Cancer Epidemiol Biomarkers Prev 10:1047,2001-1053,"},{"key":"R47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05036-9"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.02.9934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:16:58Z","timestamp":1653513418000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.02.9934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"alternative-id":["10.1200\/JCO.2005.02.9934"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.02.9934","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}